The product will be marketed by Strides Pharma in the US market under its OTC brand Nuprin
Strides Shasun has received approval from the US health regulator for pain reliever drug ibuprofen.
The product will be marketed by Strides Pharma in the US market under its OTC brand Nuprin, Strides Shasun said in a BSE filing.
Quoting IRi data, Strides Shasun said the US market for ibuprofen tablets USP 200mg is approximately $520 million.
- Advertisement -
Comments are closed.